We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leading China-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong, S.A.R., China Stock Exchange.
Qiming's portfolio company Zai Lab, an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong, S.A.R., China Limited today.